<html><head><link rel="stylesheet" href="https://unpkg.com/mvp.css"></head><title>National Policy on Rare Diseases</title><body><h1>National Policy on Rare Diseases</h1><p style="text-align:justify">A draft National Policy for Rare Diseases has been finalized and placed on the website of the Ministry of Health and Family Welfare with a view to elicit comments / views of the stakeholders, including the States/UTs and the general public by 15-02-2020. </p>
<p style="text-align:justify">The draft policy provides for lowering the incidence of rare diseases based on an integrated preventive strategy encompassing awareness generation and screening programmes and, within the constraints on resources and competing health care priorities, enable access to affordable health care to patients of rare diseases which are amenable to one-time treatment. </p>
<p style="text-align:justify">The draft policy has noted that number of persons suffering from diseases considered rare globally, is lacking in India and accordingly provides that for the purpose of the policy the term rare diseases shall construe three goup of disorders identified and categorised by experts based on their clinical experience. Considering the limited data available on rare diseases, and in the light of competing health priorities, the focus of the dradt policy is on prevention of rare diseases as a priority for all the three groups of rare diseases identified by experts.  </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">List of identified rare diseases covered for treatment under the Umbrella Scheme of RashtriyaArogyaNidhi</p>
<p style="text-align:justify">Group 1: Disorders amenable to one time curative treatment:</p>
<p style="text-align:justify"> </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">Group 2: Diseases requiring long term / lifelong treatment having relatively lower cost of treatment and benefit has been documented in literature and annual or more frequent surveillance is required: </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">b)    Disorders that are amenable to other forms of therapy (hormone/ specific drugs) </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">Group 3:  Diseases for which definitive treatment is available but challenges are to make optimal patient selection for benefit, very high cost and lifelong therapy.</p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">3a) Based on the literature sufficient evidence for good long-term outcomes exists for the following disorders   </p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">3b) For the following disorders for which the cost of treatment is very high and either long term follow up literature is awaited or has been done on small number   of patients</p>
<p style="text-align:justify"> </p>
<p style="text-align:justify">The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey stated this in a written reply in the Lok Sabha here today.</p>
<p style="text-align:justify">
</body></html>